How many institutions held PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share in Q2 2025?

74 institutional investors reported PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share for Q2 2025. Use the holders table for investor-level position and value details.

Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS)

Q: What does CUSIP 747324101 represent in this 13F holders report?

CUSIP 747324101 is the security identifier for PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

CUSIP: 747324101

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 62,130,557
Total 13F shares: 27,457,764
Share change: -2,790,134
Total reported value: $30,197,446
Price per share: $1.10
Number of holders: 74
Value change: -$2,879,012
Number of buys: 35
Number of sells: 52

Quarterly Holders Quick Answers

What is CUSIP 747324101?
CUSIP 747324101 identifies PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 747324101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PFIZER INC	3/4/5 13F	10%+ Owner · Company	11% from 13F	7,032,770	$19,410,445	—	17 Mar 2023	3/4/5 13F
Lara Sullivan	13D/G 3/4/5	Lara Sullivan, M.D. · President ,CEO & CMO, Director	11%	7,543,007	$7,844,727	+$955,040	31 Mar 2025	13D/G 3/4/5
Pamela Ann Connealy	3/4/5	CFO & COO	— mixed-class rows	2,729,049 mixed-class rows	$4,987,686	—	31 Mar 2025	3/4/5
BARCLAYS PLC	3/4/5 13F	10%+ Owner · Company	0.09% from 13F	3,477,975	$4,869,165	—	26 Apr 2022	3/4/5 13F
Bayer World Investments B.V.	3/4/5	Former 10% Owner	— class O/S missing	2,742,338	$3,839,273	—	13 Oct 2021	3/4/5
Laurion Capital Management LP	13F	Company	5.8%	3,625,974	$3,553,092	—	31 Mar 2025	13F
BlackRock, Inc.	13F 13D/G	Company	1.5% from 13D/G	3,271,974	$3,206,208	—	31 Mar 2025	13F 13D/G
INTEGRATED CORE STRATEGIES (US) LLC	13D/G	Millennium Management LLC	4%	2,488,079	$2,587,602	-$698,942	31 Mar 2025	13D/G
MILLENNIUM MANAGEMENT LLC	13F	Company	4%	2,485,276	$2,435,322	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	3.9%	2,436,728	$2,387,994	—	31 Mar 2025	13F
Cormorant Asset Management, LP	3/4/5	Former 10% Owner	— class O/S missing	1,118,854	$1,566,396	—	13 Oct 2021	3/4/5
Jay Feingold	3/4/5	Chief Medical Officer	— mixed-class rows	747,862 mixed-class rows	$1,089,573	—	24 Mar 2023	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.8%	1,109,098	$1,087,012	—	31 Mar 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	1.8%	1,100,000	$1,077,890	—	31 Mar 2025	13F
Palo Alto Investors LP	13F	Company	1.7%	1,037,421	$1,016,569	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	1.5%	932,198	$913,461	—	31 Mar 2025	13F
Aberdeen Group plc	13F	Company	1.5%	913,045	$894,693	—	31 Mar 2025	13F
Ikarian Capital, LLC	13F	Company	0.99%	613,253	$600,927	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.94%	582,136	$570,435	—	31 Mar 2025	13F
683 Capital Management, LLC	13F	Company	0.89%	550,000	$538,946	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.72%	446,482	$437,508	—	31 Mar 2025	13F
Ken Kobayashi	3/4/5	Chief Medical Officer	— class O/S missing	110,878	$424,663	—	29 Dec 2023	3/4/5
UBS Group AG	13F	Company	0.64%	396,844	$388,908	—	31 Mar 2025	13F
PIER 88 INVESTMENT PARTNERS LLC	13F	Company	0.63%	390,960	$383,102	—	31 Mar 2025	13F
Ridgeback Capital Investments L.P.	13D/G	—	0.6%	359,231	$373,600	$0	31 Dec 2024	13D/G
NORTHERN TRUST CORP	13F	Company	0.6%	373,716	$366,204	—	31 Mar 2025	13F
Decheng Capital LLC	13F	Company	0.53%	326,810	$320,241	—	31 Mar 2025	13F
Bank of New York Mellon Corp	13F	Company	0.44%	272,769	$267,287	—	31 Mar 2025	13F
Ronald Herbst	3/4/5	Chief Scientific Officer	— mixed-class rows	118,674 mixed-class rows	$234,796	—	07 Oct 2021	3/4/5
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.29%	181,042	$177,403	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.26%	160,830	$157,597	—	31 Mar 2025	13F
Nuveen, LLC	13F	Company	0.2%	127,304	$124,745	—	31 Mar 2025	13F
Ritu Shah	3/4/5	Chief Operating Officer	— class O/S missing	31,344	$120,048	—	07 Oct 2021	3/4/5
SCHULHOFF & CO INC	13F	Company	0.2%	122,000	$119,547	—	31 Mar 2025	13F
NewEdge Wealth, LLC	13F	Company	0.19%	116,006	$113,674	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.19%	115,237	$112,921	—	31 Mar 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.16%	96,652	$95,000	—	31 Mar 2025	13F
FMR LLC	13F	Company	0.14%	86,655	$84,913	—	31 Mar 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.14%	84,122	$81,000	—	31 Mar 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.13%	80,795	$79,171	—	31 Mar 2025	13F
Fan Yu	13F	Individual	0.11%	69,303	$67,910	—	31 Mar 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.11%	68,156	$66,785	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.1%	64,888	$63,584	—	31 Mar 2025	13F
Cable Car Capital, LP	13F	Company	0.1%	61,606	$60,368	—	31 Mar 2025	13F
SEI INVESTMENTS CO	13F	Company	0.1%	61,140	$59,911	—	31 Mar 2025	13F
UNIVERSITY OF CHICAGO	13F	Company	0.08%	48,731	$47,752	—	31 Mar 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.07%	45,128	$44,221	—	31 Mar 2025	13F
COMMONWEALTH EQUITY SERVICES, LLC	13F	Company	0.07%	43,250	$42,000	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.06%	40,323	$39,476	—	31 Mar 2025	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.06%	40,270	$39,461	—	31 Mar 2025	13F

Institutional Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) as of Q2 2025

As of 30 Jun 2025, Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) was held by 74 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 27,457,764 shares. The largest 10 holders included Pfizer Inc, Laurion Capital Management LP, MILLENNIUM MANAGEMENT LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Palo Alto Investors LP, BlackRock, Inc., Aberdeen Group plc, 683 Capital Management, LLC, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 74 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

-14

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.